Amylyx Pharmaceuticals, Inc.
Financials
Valuation Metrics
Amylyx Pharmaceuticals, Inc.'s Market Cap is $3.12B. At end of 2025 it was $1.14B. Ranked #1656 of 3,118 in US market (top 53%), #586 of 1,474 on NASDAQ (top 40%), #98 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 37%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.12B | US#1,656/3,118 Sec#98/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-152M | US—/3,118 Sec—/265 |
| Total Assets | $265M | US#2,930/3,118 Sec#219/265 |
| Net Assets | $239M | US#2,604/3,118 Sec#172/265 |
| Employees | 136 | US#2,560/3,118 Sec#154/265 |
| Value | ||
| P/B | 13.04x | US#2,705/3,118 Sec#202/265 |
| FCF Yield | -4.06% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -63.59% | US#2,721/3,118 Sec#180/265 |
| ROA | -57.49% | US#3,006/3,118 Sec#228/265 |
| Financial Health | ||
| Debt Ratio | 10.62% | US#117/3,118 Sec#53/265 |
| Total Debt | $5M | US#2,885/3,118 Sec#214/265 |
| FCF | $-127M | US#2,684/3,118 Sec#164/265 |
| Cash | $49M | US#2,572/3,118 Sec#223/265 |
| Current Ratio | 12.12x | US#199/3,118 Sec#61/265 |
| Performance | ||
| 1Y Return | 101.33% | US#132/3,118 Sec#34/265 |
| 1M Return | 0.92% | US#1,864/3,118 Sec#122/265 |
| From 52W High | -31.83% | US#1,933/3,118 Sec#122/265 |
| 1Y MDD | -33.59% | US#1,549/3,118 Sec#80/265 |
| Trading | ||
| Volume | 972,936 shares | US#1,706/3,118 Sec#166/265 |
| Trading Value | $28M | US#1,816/3,118 Sec#133/265 |
| Per Share | ||
| EPS | $-1.37 | US—/3,118 Sec—/265 |
| BPS | $2.15 | US#2,559/3,118 Sec#175/265 |
Company Info
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.